Your search for esrd returned 46 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Home remove

Your search for esrd returned 46 results

Sort Results:

Relevant Recent
News, Uncategorized

Vemlidy Labeling Updated With Dosing Info for Patients With ESRD

The Food and Drug Administration (FDA) has approved a labeling update for Vemlidy (tenofovir alafenamide; Gilead Sciences) to include dosage information regarding its use in adults with end-stage renal disease (ESRD; CrCl <15mL/min) who are receiving chronic hemodialysis.
News

Renal Impairment Labeling Updates for Sofosbuvir-Based HCV Therapies

The FDA has approved updated labeling for Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir) and Vosevi (sofosbuvir/velpatasvir/voxilaprevir) to include updated information regarding treatment of patients with hepatitis C virus (HCV) who have severe renal impairment including those with end stage renal disease who are on dialysis.
News

Growing Uncertainty in BP Treatment Targets

A new study has found that blood pressure (BP) below and above the current Eighth Joint National Committee (JNC 8) recommended targets is linked to an increased risk of renal disease and mortality.
Drugs in the Pipeline

Phase 3 Long-Term Study of Zerenex for Hyperphosphatemia in ESRD

Keryx Biopharmaceuticals announced top-line results from the long-term Phase 3 study of Zerenex (ferric citrate), for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
News

Healthy Diet May Cut Premature Mortality Risk in CKD Patients

For patients with chronic kidney disease (CKD), a diet that stresses healthy food vs. individual ingredients may help reduce the risk of early death, a study published in the Clinical Journal of the American Society of Nephrology has found.
Drugs in the Pipeline

Sotatercept Effective at Increasing Hemoglobin in Trial

Acceleron and Celgene announced interim data from the Phase 2a study of sotatercept (ACE-011), demonstrating dose dependent increases in hemoglobin in patients with end stage renal disease (ESRD) on hemodialysis.